Abel Hall LLC’s ARS Pharmaceuticals SPRY Stock Holding History

Abel Hall LLC’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$84.4K	Buy	+10,536	New	+$90.6K	0.01%	855

Other funds holding SPRY

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

Norman Fields Gottscho Capital Management New York $330M AUM 27.75% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

CX Institutional Auburn, Indiana $3.46B AUM 21.89% 1-Year Est. Return

Abel Hall LLC's SPRY Position: Q2 2026 in Review

Abel Hall LLC opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 10,536 shares worth $84.4K. The stake represents 0.01% of the portfolio and ranks #855 among its holdings.

27 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

Abel Hall LLC held 10,536 shares of ARS Pharmaceuticals worth $84.4K as of Q2 2026.
ARS Pharmaceuticals was a new Abel Hall LLC position in Q2 2026.
ARS Pharmaceuticals made up 0.01% of Abel Hall LLC's portfolio in Q2 2026, its #855 holding.
27 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.